Industry-Sponsored Satellite Symposia

Open to all ACG 2021 attendees, industry-sponsored satellite symposia provide additional educational opportunities for attendees. These programs are independent of the ACG 2021 Annual Scientific Meeting & Postgraduate Course programs. ACG is not the continuing medical education provider of these programs.

Friday, October 22

* Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Evan S. Dellon, MD, MPH, FACG (Chair); Amal H. Assa'ad, MD; Kathryn A. Peterson, MD, MSCI
5:30 pm – 7:30 pm • Mandalay Bay Ballroom L
Although there are no FDA-approved therapies for the treatment of eosinophilic esophagitis (EoE), targeted biologic therapies already approved for other type 2 inflammatory disorders appear promising for the treatment of EoE. During this educational event, experts will discuss the diagnosis of pediatric and adult EoE, the current standard of care, and novel and emerging treatments that may be the future of EoE management.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Live Meeting Registration Page:
Live Web Broadcast Registration Page:

Gut Decisions – Bowel Urgency in Ulcerative Colitis

Bincy P. Abraham, MD, FACG
7:30 pm – 9:30 pm • Breakers EF
Please join us as we explore the impact of bowel urgency for those with moderate-to-severe ulcerative colitis so we can work to improve outcomes relative to urgency.
This presentation is sponsored by Lilly.

Saturday, October 23

*** Connecting the Dots: Using a Positive Diagnostic Strategy to Improve the Management of Abdominal Symptoms in Irritable Bowel Syndrome with Constipation

Lin Chang, MD, FACG; Gregory Sayuk, MD, MPH
12:45 pm – 1:45 pm • Oceanside Ballroom C
Abdominal symptoms such as pain, bloating, and general discomfort are common features of irritable bowel syndrome (IBS) and result in substantial impact on the quality of life and function of affected individuals. Recent clinical guidelines encourage the use of a positive strategy to IBS-C diagnosis, resulting in shortened times to appropriate therapy, reduction in health care costs, and expedited alleviation of disease burden. This symposium will provide clinical pearls on making a confident diagnosis of IBS-C and will offer therapeutic strategies for the global management of IBS-C, including patients’ abdominal symptoms. Expert clinicians will discuss insights into the implementation of individualized treatment plans as well as effective communication approaches to the IBS-C patient.
This program is sponsored by AbbVie and Ironwood.

* Ulcerative Colitis Patient Waiting Room: From Guidelines to the Clinic

David T. Rubin, MD, FACG (Chair); Maria T. Abreu, MD; Uma Mahadevan, MD, FACG
12:45 pm – 1:45 pm • Oceanside Ballroom B
If you’ve seen one UC patient, you’ve seen ‘em all?  Definitely not! Hear the expert best practices for treating the spectrum of patients.
This activity is supported by an educational grant by Takeda Pharmaceuticals U.S.A., Inc.

*** WHEN IS IBS MORE THAN “JUST” IBS? Sorting through common causes of functional diarrhea in clinical practice.

Brooks D. Cash, MD, FACG (Chair); Lin Chang, MD, FACG; Lucinda A. Harris, MD, FACG; Satish S.C. Rao, MD, PhD, FACG
5:30 pm – 7:00 pm • Oceanside Ballroom A
In this program, the faculty will discuss practical strategies for recognizing and differentiating irritable bowel syndrome with diarrhea from other conditions with overlapping symptoms.
Supported by an educational grant from QOL Medical, LLC.
For more information and to register, please visit:

Crohn’s Disease: Targets, Risk Stratification, and Clinical Tools

Parambir Dulai, MD (Chair); Millie D. Long, MD, MPH, FACG; David T. Rubin, MD, FACG
5:30 pm – 7:30 pm • Oceanside Ballroom D
Join us for this live CME/MOC event, where Drs. Dulai, Long, and Rubin share real-world insights for treat-to-target strategies in Crohn’s disease (CD), clinical decision support tools, and a personalized approach to achieving and maintaining remission. Learn about state-of-the art tools for assessing the risk of CD progression and hear from an experienced patient about how to communicate risk and improve patient quality of life.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

** When is IBD a Pain in the Back?

Jose Scher, MD; David P. Hudesman, MD, FACG
7:30 pm – 9:30 pm • Oceanside Ballroom C
Inflammatory Bowel Disease (IBD) is often associated with multiple extraintestinal manifestations including axial spondyloarthritis. Sacroiliitis specifically remains underdiagnosed and in patients positive for sacroiliitis, back pain is the most significant clinical symptom assessed among gastroenterology outpatient visits.
This program is sponsored by UCB, Inc.

* Burning Questions in Eosinophilic Esophagitis

Ikuo Hirano, MD, FACG; Seema S. Aceves, MD, PhD; Kathryn Peterson, MD, Msci
8:00 pm – 9:15 pm • Oceanside Ballroom B
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by eosinophilic infiltration of the esophageal mucosa. EoE is associated with poor health-related quality of life (QoL), disrupting and restricting daily life for patients and their caregivers. This live and virtual symposium will feature a quickfire Q&A style discussion on the pathophysiology, diagnosis, and evidence-based treatment for EoE, to equip clinicians to manage diverse patient cases of EoE.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Sunday, October 24

* The Current and Evolving Landscape of Care: The Microbiome and Recurrent Clostridioides Difficile Infection

Paul Feuerstadt, MD, FACG; Sahil Khanna, MBBS, MS; Teena Chopra, MD, MPH
12:35 pm – 1:35 pm • Oceanside Ballroom D
Clostridioides difficile infection (CDI), a gram-positive nosocomial bacterial infection of the gut, is the most common pathogen causing healthcare–associated infection in the United States. Although CDI is normally kept in check by a healthy gut microbiome, dysbiosis allows C. difficile to multiply and produce toxins that injure the lining of the colon, producing diarrhea, inflammation, and sometimes dehydration, intestinal bleeding, toxic megacolon, and even death. Even after treatment, up to one-third of patients have recurrent CDI (rCDI). In this live CME event, 3 experts will discuss the role of the microbiome in gut health, diagnosis, current management strategies for CDI and rCDI, and latest clinical data on emerging therapies.
This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc.

* Data-Driven Decisions in Crohn’s Disease: Positioning Patients for Success

David T. Rubin, MD, FACG; Oriana M. Damas, MD; Millie D. Long, MD, MPH, FACG; Miguel D. Rigueiro, MD, FACG
7:30 pm – 9:30 pm • Oceanside Ballroom A
This CME Outfitters symposium will address suboptimal clinician knowledge and performance in positioning therapy for individual patients based on the individual characteristics of their disease by focusing on incorporating these characteristics into treatment decisions based on evidence-based recommendations, differentiating biologic therapies, and developing data-driven treatment algorithms.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

* The Changing Landscape in EGIDs Beyond the Esophagus

Evan S. Dellon, MD, MPH, FACG; Seema S. Aceves, MD, PhD; Ikuo Hirano, MD, FACG
7:30 pm – 8:30 pm • Oceanside Ballroom D
Eosinophilic gastrointestinal diseases (EGIDs) are serious, chronic, inflammatory digestive disorders characterized by excessive infiltration of eosinophils into gastrointestinal (GI) tissues. Lengthy diagnostic delays are common and often result in disease progression and missed treatment opportunities. In this live CME event, 3 experts will discuss the pathophysiology, diagnosis, and treatment of EGIDs below the esophagus. They will present the latest evidence for the efficacy of specialized diets and promising emerging pharmacologic agents that may soon alter the course of these diseases for many patients.
Supported by an independent educational grant from Allakos.

Monday, October 25

*** Hiding in Plain Sight: Exocrine Pancreatic Insufficiency in Pancreatic Diseases
Practical Approaches for the Healthcare Professional

J. Enrique Domínguez-Muñoz, MD, PhD
6:30 am – 7:30 am • Oceanside Ballroom C
Clinical manifestations of exocrine pancreatic insufficiency (EPI) can be nonspecific, resulting in delayed diagnosis. EPI leads to nutritional deficiencies, which may increase the risk of clinical complications among patients with pancreatic disease. During the program, data on EPI burden of disease along with clinical pearls related to EPI diagnosis and management will be shared.
This program is sponsored by AbbVie.

* Keeping Things Moving in the Treatment of Chronic Idiopathic Constipation: Exploring the Evidence and Guidelines Through Case Studies

William D. Chey, MD, FACG; Michael Camilleri, MD, MACG; Lucinda A. Harris, MD, FACG
7:00 pm – 9:00 pm • Oceanside Ballroom A
This CME Outfitters symposium will focus on how to differentiate CIC from constipation-predominant irritable bowel syndrome (IBS-C) for early and accurate diagnosis and will provide data on current therapies used in the management of CIC in order for clinicians to better understand how to develop comprehensive treatment strategies.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

* Small Molecules, Big Breakthroughs in Ulcerative Colitis

David T. Rubin, MD, FACG (Chair); Maria T. Abreu; Stephen B. Hanauer, MD, MACG
7:00 pm – 9:00 pm • Oceanside Ballroom D
Oral small molecule drugs represent breakthroughs in the treatment and management of ulcerative colitis. This CME/CE symposium will provide a historical and clinical overview of both current and emerging small molecules for UC and expert panel discussions on where these drugs best fit within the UC treatment paradigm.
This continuing medical education activity is supported through an educational grant from Arena Pharmaceuticals, Inc.

Tuesday, October 26

* Exploring New Frontiers in the Management of H. pylori Infection

William D. Chey, MD, FACG; Colin W. Howden, MD, FACG; Shailja C. Shah, MD, MPH
6:30 am – 7:30 am • Oceanside Ballroom C
Helicobacter pylori, a gram-negative flagellate bacterium, is responsible for infection of the gastric lining in approximately 35% of the US adult population. Untreated or undertreated H. pylori infection results in considerable morbidity and mortality. But – there is good news! A new class of pharmacotherapies holds promise for patients with H. pylori infection who fail primary treatment due to antimicrobial resistance.  During this live symposium, our expert faculty will discuss the latest guideline recommendations for treatment of H. pylori infection, as well as the potential role of new therapies. Our experts will also examine how new and emerging treatments for H. pylori infection can help to optimize patient outcomes. 
Supported by an independent educational grant from Phathom Pharmaceuticals.

*Session will be live-streamed on the ACG Virtual Conference Platform at the date and time listed above.
**Session will be recorded and will be made available on the ACG Virtual Conference Platform after the live program.
***Session will be both live-streamed and recorded and will be available on the ACG Virtual Conference Platform.